Cam Group Holding A Cut By $570,802 Its Biomarin Pharmaceutical (BMRN) Holding, Great Point Partners Has Increased Enanta Pharmaceuticals (ENTA) Holding By $1.26 Million

Great Point Partners Llc increased Enanta Pharmaceuticals Inc (ENTA) stake by 4.84% reported in 2016Q4 SEC filing. Great Point Partners Llc acquired 38,253 shares as Enanta Pharmaceuticals Inc (ENTA)’s stock rose 26.08%. The Great Point Partners Llc holds 828,253 shares with $27.75 million value, up from 790,000 last quarter. Enanta Pharmaceuticals Inc now has $680.42 million valuation. The stock declined 3.11% or $1.05 reaching $32.66 on the news. About 108,214 shares traded. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 26.87% since October 3, 2016 and is uptrending. It has outperformed by 15.97% the S&P500.

Cam Group Holding A decreased Biomarin Pharmaceutical Inc (BMRN) stake by 3.62% reported in 2016Q4 SEC filing. Cam Group Holding A sold 6,961 shares as Biomarin Pharmaceutical Inc (BMRN)’s stock declined 12.19%. The Cam Group Holding A holds 185,224 shares with $15.34 million value, down from 192,185 last quarter. Biomarin Pharmaceutical Inc now has $15.78B valuation. The stock declined 1.26% or $1.15 reaching $90 per share. About 271,324 shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has declined 3.38% since October 3, 2016 and is downtrending. It has underperformed by 14.29% the S&P500.

Since November 29, 2016, it had 0 insider buys, and 2 selling transactions for $926,114 activity. On Wednesday, January 4 Or Yat Sun sold $488,505 worth of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) or 13,921 shares.

Investors sentiment decreased to 1.47 in Q4 2016. Its down 0.06, from 1.53 in 2016Q3. It turned negative, as 13 investors sold ENTA shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported. Ajo Limited Partnership owns 200,422 shares or 0.03% of their US portfolio. Krensavage Asset Ltd Liability Company accumulated 1.06M shares or 12.68% of the stock. Walleye Trading Limited holds 0% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 9,500 shares. Shell Asset Management invested in 15,946 shares. State Of Tennessee Treasury Department accumulated 0% or 10,446 shares. Clarivest Asset Mgmt Ltd invested in 0.01% or 13,300 shares. Fmr Llc holds 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) or 391,815 shares. Blackrock Mgmt Limited Liability Company holds 85,043 shares or 0% of its portfolio. Northern Tru holds 190,311 shares or 0% of its portfolio. Granahan Investment Mngmt Inc Ma has invested 0.57% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Utd Svcs Automobile Association reported 0.01% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Loomis Sayles & LP reported 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Blackrock Japan Ltd has invested 0% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Tudor Inv Et Al accumulated 15,470 shares. Blackrock Advisors Limited Liability Corporation reported 37,209 shares.

Among 4 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Enanta Pharmaceuticals Inc had 11 analyst reports since August 7, 2015 according to SRatingsIntel. The firm earned “Underweight” rating on Friday, October 23 by Barclays Capital. The firm has “Overweight” rating given on Tuesday, August 9 by JP Morgan. The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has “Buy” rating given on Friday, August 7 by Zacks. The stock has “Mkt Outperform” rating by JMP Securities on Friday, October 23. The firm earned “Market Perform” rating on Thursday, April 28 by JMP Securities. As per Saturday, August 8, the company rating was downgraded by TheStreet.

Cam Group Holding A increased Cara Therapeutics Inc (NASDAQ:CARA) stake by 51,820 shares to 319,820 valued at $2.97 million in 2016Q4. It also upped Johnson & Johnson (NYSE:JNJ) stake by 50,287 shares and now owns 317,773 shares. Lilly Eli & Co (NYSE:LLY) was raised too.

Among 20 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 13 have Buy rating, 0 Sell and 7 Hold. Therefore 65% are positive. BioMarin Pharmaceutical had 42 analyst reports since August 5, 2015 according to SRatingsIntel. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Overweight” rating by Morgan Stanley on Tuesday, February 7. The firm earned “Perform” rating on Tuesday, February 23 by Oppenheimer. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Cowen & Co on Tuesday, August 25. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Perform” rating by Oppenheimer on Wednesday, November 18. On Tuesday, January 19 the stock rating was maintained by Wedbush with “Neutral”. The rating was maintained by Piper Jaffray on Friday, August 5 with “Overweight”. William Blair maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Wednesday, August 5 with “Buy” rating. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Outperform” rating by BMO Capital Markets on Thursday, April 7. The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) earned “Buy” rating by Jefferies on Tuesday, August 25. The stock has “Neutral” rating by Piper Jaffray on Monday, November 7.